摘要
艾滋病病毒(HIV)和乙型肝炎病毒(HBV)传播途径相似,两者共感染在临床工作中十分常见。随着抗病毒治疗的广泛覆盖及早期启动,HIV感染者的预期寿命和生活质量大大提高。但研究显示,即使能够有效抑制HIV和HBV的复制,HIV-HBV共感染者的发病率和病死率还是明显高于HIV或HBV单独感染者,尤其是这两种病毒都具有长期存活的形式,使得其抗病毒治疗都要持续终身。如何寻找有效、安全、方便的长期抗病毒治疗方案和进一步降低HBV相关肝病发病率及病死率是HIV-HBV共感染研究的另一挑战。本文就HIV-HBV共感染的相互影响及其机制以及治疗进展做一综述。
The pathways for HIV transmission and hepatitis B virus(HBV) are similar, and co-infection is common in clinical work. With the coverage and early initiation of antiviral therapy(ART), the life expectancy and quality of life of people living with HIV have increased significantly. However, studies show that the incidence and mortality of HIV-HBV co-infected patients are significantly higher than those of HIV or HBV infection alone even if the replication of HIV and HBV can be effectively inhibited, as both viruses can survive for a long time and ART will have to last for life time. The challenges for HIV-HBV co-infection treatment is to find the effective, safe and convenient long-term ART regimens so as to reduce the incidence and mortality of HBV-related liver diseases. This article reviews the interaction of HIV-HBV co-infection and its mechanism and treatment progress.
作者
郭小玲
代丽丽
王建云
GUO Xiaoling;DAI Lili;WANG Jianyun(Department of Infectious Diseases,Lanzhou Pulmonary Hospital,Lanzhou 730000;,Gansu,China,2.Center of Infectious Diseases,Beijing You'an Hospital,Capital Medical University,Beijing 100069)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2020年第2期217-221,共5页
Chinese Journal of Aids & STD
关键词
艾滋病病毒
乙型肝炎病毒
共感染
抗病毒治疗
肝纤维化
human immunodeficiency virus
hepatitis B virus
co-infection
antiviral therapy
liver fibrosis
